GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
NCT04747431 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE1 / PHASE2
Lead sponsorPassage Bio, Inc.
Last update2026-10-29
Public-record facts
| Intervention | PBFT02 (DRUG) |
|---|---|
| Condition | Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72 |
| Enrollment | 30 |
| Why stopped | The PBFT02-001 Study was terminated by the Sponsor, Passage Bio, Inc., due to strategic company resourcing decisions. The early closure is not related to safety, efficacy, or any change in the benefit-risk profile of the investigational product. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-29.
- It is an interventional PHASE1/PHASE2 study with a named drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT04747431. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.